GlassScriptPhysician profile
Mariame Diabate
NPI 1164021671
$2,581.34
in general payments reported to CMS, 2019-2025
24 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $744 · 2023: $551 · 2024: $436 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $324.63 | 2023-2025 | Veozah |
| Abbvie INC. | $308.65 | 2021-2024 | |
| Organon LLC | $256.20 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $243.31 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $239.25 | 2022-2025 | |
| Coopersurgical, INC. | $233.77 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $123.47 | 2021-2022 | |
| Exeltis, USA INC. | $109.36 | 2021-2023 | Slynd |
| Sumitomo Pharma America, INC. | $85.56 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $80.18 | 2022-2025 | Zurzuvae |
| Shield Therapeutics INC | $73.29 | 2023-2024 | Accrufer |
| Avion Pharmaceuticals | $68.20 | 2021-2023 | Balcoltra |
| Ethicon US, LLC | $64.60 | 2021-2024 | Harmonic, Stratafix, Ethicon |
| Aspira Women'S Health INC | $62.51 | 2022-2023 | Ova1 |
| Pfizer INC. | $60.81 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renovia INC | $56.02 | 2021 | |
| Hologic Sales and Service, LLC | $41.16 | 2023-2024 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Sanofi Pasteur INC. | $34.96 | 2024 | |
| Becton, Dickinson and Company | $25.35 | 2024 | Bd Max System, Bd Max Instrument |
| Merck Sharp & Dohme LLC | $22.24 | 2021 | |
| Medtronic, INC. | $19.41 | 2024 | V-Loc 180 |
| Millicent US INC | $18.48 | 2025 | Femlyv |
| Myovant Sciences INC. | $16.05 | 2022 | |
| Evofem Biosciences, INC. | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariame Diabate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.